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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
spermidine and prolongation of the growing phase (anagen) of the hair 
cycle pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Giuliani S.p.A., submitted pursuant to Article 13(5) of Regulation (EC) No 
1924/2006 via the Competent Authority of Italy, the Panel on Dietetic Products, Nutrition and Allergies was 
asked to deliver an opinion on the scientific substantiation of a health claim related to spermidine and 
prolongation of the growing phase (anagen) of the hair cycle. The scope of the application was proposed to fall 
under a health claim referring to a health claim based on newly developed scientific evidence and including a 
request for the protection of proprietary data. The food constituent that is the subject of the health claim is 
spermidine, which is sufficiently characterised. The claimed effect is prolongation of the growing phase (anagen) 
of the hair cycle. The target population proposed by the applicant is “healthy people affected by chronic telogen 
effluvium”. Following EFSA’s request to provide a rationale why subjects with chronic telogen effluvium would 
be an appropriate study population for the scientific substantiation of a health claim intended for the general 
population, the applicant indicated that telogen effluvium is caused by multifactorial triggers, occurs in both 
sexes at any age, and that it could be considered to affect the general population. From the evidence provided by 
the applicant the Panel considers that the claimed effect is related to the treatment of pathological conditions 
leading to shortening of the anagen phase of hair growth. The Panel concludes that the claimed effect is related 
to the treatment of a disease and does not comply with the criteria laid down in Regulation (EC) No 1924/2006. 
© European Food Safety Authority, 2011 
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SUMMARY  
Following an application from Giuliani S.p.A., submitted pursuant to Article 13(5) of Regulation (EC) 
No 1924/2006 via the Competent Authority of Italy, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to 
spermidine and prolongation of the growing phase (anagen) of the hair cycle. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence and including a request for the protection of proprietary data. 
The food constituent that is the subject of the health claim is spermidine. Spermidine 
(N-(3-aminopropyl)butane-1,4-diamine) is a polyamine which is present in nearly all eukaryotic cells. 
The Panel considers that spermidine, which is the subject of the health claim, is sufficiently 
characterised. 
After clarification requested by EFSA, the applicant indicated that the claimed effect to be considered 
for evaluation is “prolongation of the growing phase (anagen) of the hair cycle”. The target population 
proposed by the applicant is “healthy people affected by chronic telogen effluvium”. 
The applicant was asked to provide a rationale why subjects with chronic telogen effluvium would be 
an appropriate study population for the scientific substantiation of a health claim intended for the 
general population. The applicant indicated that telogen effluvium is caused by multifactorial triggers, 
occurs in both sexes at any age, and that it could be considered to affect the general population. 
From the evidence provided by the applicant the Panel considers that the claimed effect is related to 
the treatment of pathological conditions leading to shortening of the anagen phase of hair growth. The 
Panel concludes that the claimed effect is related to the treatment of a disease and does not comply 
with the criteria laid down in Regulation (EC) No 1924/2006. 
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BACKGROUND  
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health), which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the Community 
list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA: 
 The application was received on 07/07/2011. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence and including a request for the protection of proprietary data. 
 On 21/07/2011, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 The applicant provided the missing information on 05/08/2011. 
 The scientific evaluation procedure started on 30/08/2011. 
 During the meeting on 23/11/2011, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to spermidine and 
prolongation of the growing phase (anagen) of the hair cycle. 
TERMS OF REFERENCE  
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion 
on the scientific substantiation of a health claim related to: spermidine and prolongation of the 
growing phase (anagen) of the hair cycle. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of spermidine, a positive assessment of its safety, nor a decision on whether spermidine is, or is not, 
classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework of 
Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Giuliani S.p.A., Via Palagi 2, 20129 Milano, Italy. 
The application includes a request for the protection of proprietary data for the use of spermidine in 
accordance with Article 21 of Regulation (EC) No 1924/2006. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent for which the claim is made is spermidine. 
Health relationship as claimed by the applicant 
According to the applicant, spermidine “induces hair growth during life cycle, stimulates cell 
proliferation at hair bulb improving the growth phase (anagen), reduces hair loss and increases hair 
resistance” (as described in the first submission). Following EFSA’s request the claimed effect was 
clarified as “prolongs the growing phase (anagen) of the hair cycle”. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Spermidine prolongs the 
growing phase (anagen) of the hair cycle”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the pattern of consumption is 0.5 mg of spermidine per day that can be 
supplied by one tablet of food supplement. The proposed target population is healthy people affected 
by a condition of hair loss (chronic telogen effluvium; CTE). 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is spermidine. 
Spermidine (N-(3-aminopropyl)butane-1,4-diamine) is a polyamine which is present in nearly all 
eukaryotic cells. Under physiological conditions, polyamines are totally protonated and behave as 
natural polycations. The cellular content of these amines is closely regulated and they are synthesised 
by a highly regulated pathway from ornithine after decarboxylation (Agostinelli et al., 2010; Morgan, 
1999; Pegg, 2009). 
The applicant markets spermidine as salt - spermidine trihydrochloride (molecular formula C7H19N3 
. 
3HCl), in the form of tablets containing 0.50 mg of spermidine trihydrochloride corresponding to 
0.285 mg of spermidine free base. Complete specifications such as flow chart of the manufacturing 
process, stability and purity information, and bioavailability data have been provided. 
The Panel considers that the food constituent, spermidine, which is the subject of the health claim, is 
sufficiently characterised. 
2. Relevance of the claimed effect to human health 
Initially the claimed effect was described as “induces hair growth during life cycle, stimulates cell 
proliferation at hair bulb improving the growth phase (anagen), reduces hair loss and increases hair 
resistance”. Following EFSA’s request to clarify the claimed effect, the applicant indicated that the 
effect to be considered for evaluation is “prolongation of the growing phase (anagen) of the hair 
cycle”. The target population proposed by the applicant is “healthy people affected by chronic telogen 
effluvium (CTE)”. 
Telogen effluvium is a form of nonscarring alopecia characterised by diffuse hair shedding. Acute 
telogen effluvium is characterised by an abrupt onset, and rapid, diffuse, self-limited, excessive 
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shedding of normal club hair, usually seen 2-3 months after a triggering event e.g. febrile illness, 
emotional stress, chronic systemic illness. The term chronic telogen effluvium refers to the situation in 
which telogen hair shedding persists for longer than six months and the triggering factor is often less 
apparent (Messenger et al., 2010). Premature progression of anagen into catagen and telogen hair 
follicle is the main mechanism behind telogen effluvium. 
During the validation step of the application, the applicant was asked to provide a rationale why 
subjects with chronic telogen effluvium would be an appropriate study population for the scientific 
substantiating of a health claim intended for the general population. The applicant indicated that 
telogen effluvium is caused by multifactorial triggers, occurs in both sexes at any age, and that it could 
be considered to affect the general population. 
From the evidence provided by the applicant, the Panel considers that the claimed effect is related to 
the treatment of pathological conditions leading to shortening of the anagen phase of hair growth. 
The Panel concludes that the claimed effect is related to the treatment of a disease and does not 
comply with the criteria laid down in Regulation (EC) No 1924/2006. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, spermidine, which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect refers to reducing net hair loss by prolongation of the anagen phase of the 
hair cycle. The target population is “healthy people affected by chronic telogen effluvium”. 
 The claimed effect is related to the treatment of a disease and does not comply with the 
criteria laid down in Regulation (EC) No 1924/2006. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on spermidine and prolongation of the growing phase (anagen) of the hair 
cycle pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0308_IT). August 
2011. Submitted by Giuliani S.p.A. 
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GLOSSARY / ABBREVIATIONS 
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